Family Medicine and *Patient-Centered* Asthma Care

Presented by the
California Academy of Family Physicians
Faculty: Hobart Lee, MD

Disclosures: Jeffrey Luther, MD, Program Director, Memorial Family Medicine Residency Program in Long Beach, CA also served on the Content Development Team for this program.

Drs. Lee and Luther declare that neither they nor members of their immediate family have financial relationships with the manufacturers of goods or services discussed, or corporate supporters of this event.

Drs. Lee and Luther are not discussing or presenting information that is related to off-label or investigational use of any therapy, product, or device.

CAFP staff involved in the planning of this activity declare no financial relationships.

Hobart Lee, MD
Assistant Professor, Dept. of Family Medicine and Program Director Family Medicine Residency, Loma Linda University, Loma Linda, CA
Disclosure and Industry Support

- The CAFP Committee on Continuing Professional Development is responsible for management and resolution of conflict for any individual who may have influence on content, who have served as faculty, or who may produce CME/CPD content for the CAFP.

- It is the policy of CAFP to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities.

- This activity is supported by unrestricted educational grants from Boehringer Ingelheim and Sunovion.
Learning Objectives

- Apply latest evidence-based guidelines in the diagnosis and management of asthma.
- Use simplified, efficient processes to interpret spirometry results.
- Name the six key messages from the GIP report.
- Name several sources to identify appropriate inhalers and help patients understand importance of accurate technique when using inhalers.
- Demonstrate effective and culturally competent communication skills to improve patient engagement and adherence to asthma management plans.
Definition: Asthma

- Chronic disease of the airways that may cause
  - Wheezing
  - Breathlessness
  - Chest tightness
  - Nighttime or early morning coughing
- Episodes are usually associated with widespread, but variable, airflow obstruction within the lung that is often reversible either spontaneously or with treatment
Current Asthma Prevalence Percents by Age, Sex, and Race, United States, 2010

- Child: 9.4%
- Adult: 8.2%
- Male: 7.0%
- Female: 9.9%
- White: 8.1%
- Black: 12.1%
- Hispanic: 7.3%

Source: National Health Interview Survey, National Center for Health Statistics, Centers for Disease Control and Prevention

© 2013/California Academy of Family Physicians
Burden: Every day in America

- 44,000 people have an asthma attack.
- 36,000 kids miss school due to asthma.
- 27,000 adults miss work due to asthma.
- 4,700 people visit the emergency room due to asthma.
- 1,200 people are admitted to the hospital due to asthma.
- 9 people die from asthma.
Population Disparities

- Current asthma prevalence is higher among:
  - Children than adults
  - Boys than girls
  - Women than men

- Asthma morbidity and mortality is higher among:
  - African Americans
Risk Factors

- Genetic
- Obesity
- Sex

PLUS:

- Environmental
  - Allergens
  - Infections
  - Smoke
  - Diet
  - Air Pollution

Asthma Triggers
Guidelines

- NHLBI: National Asthma Education and Prevention Program (NAEPP)
  - Expert Panel Report 3 (417 pages)
  - Guidelines Implementation Panel (GIP)
- GOLD: Global Initiative for Chronic Obstructive Lung Disease
- GINA: Global Initiative for Asthma
  - Collaborative of NHLBI and WHO
- ICSI: Institute for Clinical Systems Improvement
  - Focuses on Triple Aim
What is GIP?

- Recommendations and strategies to implement EPR-3
- Six key messages
GIP Messages

1. **Use Inhaled Corticosteroids**
   Inhaled corticosteroids are the most effective medications for long-term management of persistent asthma.

2. **Use Asthma Action Plan**
   All people who have asthma should receive a written asthma action plan to guide their self-management efforts.

3. **Asthma Severity**
   All patients should have an initial severity assessment based on measures of current impairment and future risk to determine type and level of initial therapy needed.
GIP Messages

4. **Asthma Control**
   Patients should review the level of control with their PCP to guide decisions.

5. **Schedule Follow-up Visits**
   Needed to assess asthma control and to modify treatment if needed.

6. **Allergen and Irritant Exposure Control**
   Review each patient’s sensitivity to allergens and irritants and provide a multipronged strategy to reduce exposure.
Making the Diagnosis

- Medical History
- Physical Exam
- Tests for Dx and Monitoring
  - Spirometry
  - Peak expiratory flow
Meet Samantha

Samantha is a 19-year-old college sophomore.

She’s had asthma since childhood but hasn’t seen a physician in years.

She describes symptoms 3-4 times/week and she awakens with asthma ~once/week.

Her symptoms respond to a short-acting β-agonist.
Samantha also tells you she:

- Smoked for awhile in high school, but quit after starting college
- Has an extensive history of seasonal allergies
- Plays midfield for college soccer team, but rarely has symptoms with exercise
Spirometry: Testing Lung Function
Spirometry

- **Normal**: $0.7 < \text{FEV1/FVC} < 0.8$
- **Older patients**: 0.65-0.70 may be normal
- **Younger patients**: $>0.70$ may be abnormal

- Use lower limit of normal (LLN) to help distinguish in young and old patients
You perform office spirometry. Her FEV₁ is 60% of predicted and her FEV₁/FVC ratio is 66%; these are fully reversible after short-acting bronchodilator.

What is Samantha’s diagnosis by spirometry?

0% 1. Normal
0% 2. Obstructive disease
0% 3. Restrictive disease
0% 4. Mixed obstructive/restrictive disease
## Spirometry patterns

<table>
<thead>
<tr>
<th>DIAGNOSIS</th>
<th>Spirometry values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>FEV(_1) and FVC &gt; 80%</td>
</tr>
<tr>
<td></td>
<td>FEV(_1)/FVC ratio &gt; 0.7</td>
</tr>
<tr>
<td>Obstructive</td>
<td>FEV(_1) &lt; 80%</td>
</tr>
<tr>
<td></td>
<td>FVC normal or reduced (less than FEV(_1))</td>
</tr>
<tr>
<td></td>
<td>FEV(_1)/FVC ratio &lt; 0.7</td>
</tr>
<tr>
<td>Restrictive</td>
<td>FEV(_1) normal or mildly reduced</td>
</tr>
<tr>
<td></td>
<td>FVC below 80% predicted</td>
</tr>
<tr>
<td></td>
<td>FEV(_1)/FVC ratio normal (&gt; 0.7)</td>
</tr>
<tr>
<td>Mixed</td>
<td>FEV1 reduced</td>
</tr>
<tr>
<td></td>
<td>FVC reduced</td>
</tr>
<tr>
<td></td>
<td>FEV1/FVC reduced</td>
</tr>
</tbody>
</table>
Severity

- Intensity of untreated disease
- Determined by
  - Current impairment
  - Future risk
- Guides decisions for initiating therapy
Samantha has daytime symptoms 3-4x/week and nighttime symptoms 1x/week. Her FEV₁ is 66% of predicted. She went to urgent care once this past year for asthma symptoms.

What is Samantha’s asthma severity?

- 0% 1. Intermittent
- 0% 2. Persistent - mild
- 0% 3. Persistent - moderate
- 0% 4. Persistent - severe
## Classifying Impairment

### Classification of asthma severity ≥ 12 years of age *

<table>
<thead>
<tr>
<th>Components of severity</th>
<th>Intermittent</th>
<th>Persistent-mild</th>
<th>Persistent-moderate</th>
<th>Persistent-severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>≤ 2 days per week</td>
<td>&gt; 2 days per week, not daily</td>
<td>Daily</td>
<td>Throughout the day</td>
</tr>
<tr>
<td>Nighttime awakenings</td>
<td>≤ 2 times per month</td>
<td>3 to 4 times per month</td>
<td>&gt; Once per week, but not nightly</td>
<td>Often 7 times per week</td>
</tr>
<tr>
<td>Short-acting beta agonist use for symptom control</td>
<td>≤ 2 days per week</td>
<td>2 days/wk, but no more than daily</td>
<td>Daily</td>
<td>Several times per day</td>
</tr>
<tr>
<td>Interference with normal activity</td>
<td>None</td>
<td>Minor limitation</td>
<td>Some limitation</td>
<td>Extremely limited</td>
</tr>
<tr>
<td>Lung function</td>
<td>Normal FEV&lt;sub&gt;1&lt;/sub&gt; between exacerbations; FEV&lt;sub&gt;1&lt;/sub&gt; &gt;80% of predicted; FEV&lt;sub&gt;1&lt;/sub&gt;/FVC normal</td>
<td>FEV&lt;sub&gt;1&lt;/sub&gt; ≥ 80% of predicted; FEV&lt;sub&gt;1&lt;/sub&gt;/FVC normal</td>
<td>FEV&lt;sub&gt;1&lt;/sub&gt; 60-80% of predicted; FEV&lt;sub&gt;1&lt;/sub&gt;/FVC reduced 5%</td>
<td>FEV&lt;sub&gt;1&lt;/sub&gt; &lt; 60% of predicted; FEV&lt;sub&gt;1&lt;/sub&gt;/FVC reduced &gt;5%</td>
</tr>
</tbody>
</table>
# Classifying Risk

<table>
<thead>
<tr>
<th>Exacerbations requiring systemic corticosteroids</th>
<th>Intermittent</th>
<th>Persistent Mild</th>
<th>Persistent Mod</th>
<th>Persistent Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 – 1/year</td>
<td>≥ 2/year</td>
<td>≥ 2/year</td>
<td>≥ 2/year</td>
</tr>
</tbody>
</table>

Consider severity and interval since last exacerbation; frequency and severity may fluctuate over time for patients in any severity category; relative annual risk of exacerbations may be related to FEV₁
Treatment

- Short-acting β-agonists
- Inhaled corticosteroids
- Third-line agents:
  - Long-acting β-agonists
  - Leukotriene antagonists
  - Other
Environmental Allergens

- Ask about allergens, including indoor inhalants (e.g. cigarette smoking)
- Use skin or in vitro testing to determine sensitivities and correlate with patient history
- Assess for seasonal allergies
Address Allergens and Triggers

- Reduce allergen exposure with multifaceted, comprehensive approach
- Avoid smoke/pollution, med/food sensitivities
- Consider allergen immunotherapy
- Treat co-morbid conditions
Which of the following instructions for inhaler use is not correct?

1. Shake the inhaler before using
2. Breathe out and breath in quickly as you press down on the inhaler
3. Hold your breath and count to 10 slowly
4. For short-acting rescue meds, wait about 1 minute between puffs
5. For steroid inhalers, rinse and spit your mouth after each use

0% 0% 0% 0% 0%
A Word About Inhaler Use

- Technique is critical to medication delivery
- Physician should demonstrate and observe inhaler use
- Education materials:
  - Handout
  - Video
Demonstrate inhaler technique
Ongoing Management

- Symptom control
- Activity levels / exercise
- Pulmonary function
- Prevent asthma exacerbations
- Avoid adverse effects from asthma medications
- Prevent asthma mortality
Assess and Monitor Control

- Current impairment
  - Frequency/intensity of symptoms
  - Functional limitations experienced
- Future risk
  - Likelihood of exacerbations
  - Decline in lung function
  - Risk of adverse medication effects
EPR-3: Classification of Control: Current Impairment

Symptom awareness: Same as when assessing severity

Questionnaires:
Asthma Therapy Assessment Questionnaire
Asthma Control Questionnaire
Asthma Control Test

Peak flow monitoring: Symptom monitoring as effective as peak flow monitoring in assessing asthma control

Control assessment also takes into account risk
Action Plans

Written asthma action plan is important for self-management education.

Strongest benefit for moderate/severe asthma (stage 3 or higher), history of severe exacerbations, or poorly controlled asthma
Follow-up

- 2-6 week after starting/Changing meds
- 1-6 months if stable
- Focus on communication and teaching patients did not lengthen visit times (e.g., reviewing written asthma action plan)
## Recommendations for All Subsequent Visits

<table>
<thead>
<tr>
<th>Focus on:</th>
<th>Teach in simple language:</th>
<th>Teach or review and demonstrate:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Expectations of visit</td>
<td>- Review and reinforce all:</td>
<td>- Inhaler/spacer or VHC technique.</td>
</tr>
<tr>
<td>- Asthma control</td>
<td>- Educational messages</td>
<td>- Peak flow monitoring technique, if appropriate.</td>
</tr>
<tr>
<td>- Patients' goals of treatment</td>
<td>- Environmental control strategies at home, work, or school</td>
<td>- Use of written asthma action plan. Review and adjust as needed.</td>
</tr>
<tr>
<td>- Medications</td>
<td>- Medications</td>
<td></td>
</tr>
<tr>
<td>- Quality of life</td>
<td>- Self-assessment of asthma control, using symptoms and/or peak flow as a guide</td>
<td>- Confirm that patient knows what to do if asthma gets worse.</td>
</tr>
</tbody>
</table>

Ask relevant questions from previous visits and also ask:

- “How have you tried to control things that make your asthma worse?”
- “Please show me how you use your inhaled medication.”

Sources: Adapted from Guevara et al. 2003; Janson et al. 2003; Powell and Gibson 2003; Wilson et al. 1993.
Back to Samantha: Putting her at the Center of Care

- Family & Friends
- Asthma Education
- Care Team
- Medication
- Behavioral & Cognitive
- Social Organizations
- Community
- People Like Me

© 2013/California Academy of Family Physicians
Patient Non-Adherence

**World Health Organization**

Only 50% of patients take medication as prescribed.

Non-adherence affects Americans of all ages, both genders and across socioeconomic levels

**NCPIE, August 2007**

Lack of medication adherence estimated at $177 billion annually:

- Unnecessary disease progression;
- Disease complications;
- Reduced functional abilities;
- Lower quality of life;
- Premature death

* National Council on Patient Information and Education, August 2007

© 2013/California Academy of Family Physicians
Patient-Doctor Partnership

- Communication is key!
- We are asking patients to:
  - Identify and control triggers
  - Take meds based on symptom (or peak-flow) based algorithm
  - Identify and self-treat exacerbations
  - Appropriately communicate with family physicians for additional help
Partnership and Shared-decision making

- Determine patient’s personal goals and treatment preferences
- Share general asthma goals
- Agree on shared goals of treatment
- Provide a written asthma action plan
Educate, educate, educate

- “No symptoms, no asthma” belief
- Latino ethnocultural belief that asthma is a “cold” illness
- Patient’s reading level strongest predictor of asthma knowledge and proper MDI use
Social Media and Asthma

Use-inhalers.com
Patient resources

- http://www.ginasthma.org/Patients
- http://www.patient.co.uk/health/asthma
Key Take Home Points

- Initial assessment focuses on asthma severity
- Regular follow-up needs to address control
  - Both severity and control relate to degree of impairment and future risk
- Inhaled corticosteroids are most effective for long-term management of persistent asthma
- Control of allergen/irritant exposure contributes to control
- Patient engagement and shared decision-making are key
  - Asthma action plan facilitates self-management
Thank You!

Questions
Resources

- NHLBI Guidelines for the Diagnosis and Treatment of Asthma (EPR-3)
  - [http://www.nhlbi.nih.gov/guidelines/asthma/index.htm](http://www.nhlbi.nih.gov/guidelines/asthma/index.htm)

- Global Initiative for Asthma (GINA)
  - Pocket Guide for Asthma Management & Prevention. Available from:
    - [http://www.ginasthma.org/documents/1](http://www.ginasthma.org/documents/1)
  - Global Strategy for Asthma Management and Prevention, 2012. Available from:
    - [http://www.ginasthma.org](http://www.ginasthma.org)
Action Plans

- Public Health Institute Regional Asthma Management and Prevention (RAMP) Initiative

- California Asthma Public Health Initiative, CA Dept of Health Services